Although the preferred choice for BC characterization is molecular classification (i.e., estrogen receptor (ER), progesterone receptor (RP), and receptor of human epidermal growth factor 2 (HER-2), the classification based on pathological characteristics is still the most widely used method in clinical practice [2, 3]. This evidence concerns the gene ERBB2 and breast cancer.